+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ADHD Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • PDF Icon


  • 70 Pages
  • November 2021
  • Region: Global
  • VPA Research
  • ID: 5463825
ADHD pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “ADHD pipeline drugs and companies” presents key-decision makers with critical insights into ADHD pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

ADHD pipeline Drug Snapshot, 2021

The ADHD pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for ADHD. In addition to recent status, overview of drugs is included in the study. Wide range of ADHD drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

ADHD drug development pipeline by phase

The ADHD pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all ADHD pipeline candidates is provided in the report enables you to understand timetable developments in ADHD therapeutic area.

ADHD pipeline drug Technology, Licensing and Collaboration Details

Details of technologies used for development of ADHD pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the ADHD research study. Companies looking to partner with other players are also detailed in the report.

ADHD- mechanism of action of pipeline candidates

ADHD pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different ADHD companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of ADHD drug administration.

ADHD Drugs- Preclinical and Clinical Trials

This chapter in ADHD preclinical and clinical trials assists in gaining clear understanding of the timetable developments in ADHD product area. Preclinical and clinical trial details of pipeline candidates for ADHD are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

ADHD companies and Profiles

Companies developing ADHD pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

ADHD Market Developments

The report presents the recent news and developments in the ADHD pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the ADHD R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of ADHD pipeline drugs and clinical trials
  • Identify ADHD drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the ADHD drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the ADHD pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global ADHD pipeline news, developments and insights

Scope of the Report

  • Disease overview including ADHD symptoms, widely used treatment options, companies and other details are included
  • ADHD Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • ADHD pipeline drug count by phase, company and mechanism of action
  • ADHD companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each ADHD pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • ADHD companies including their business snapshot, business description and ADHD pipelines are included.
  • Recent ADHD market developments, pipeline news and deals are provided

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 ADHD Disease overview
2.2 Companies investing in ADHD industry
3 ADHD Pipeline Snapshot, 2021
3.1 ADHD Pipeline Drugs- Dominant phase type
3.2 ADHD pipeline Drugs- Leading Mechanism of Action
3.3 ADHD Pipeline Drugs- Widely researched Route of Administration
3.4 ADHD Pipeline- New Molecular Entity
3.5 ADHD pipeline- Companies, Universities and Institutes
4. ADHD Drug Profiles
4.1 Current Status of ADHD Drug Candidates, 2021
4.2 ADHD Drugs in Development- Originator/Licensor
4.3 ADHD Drugs in Development- Route of Administration
4.4 ADHD Drugs in Development- New Molecular Entity (NME)
5. ADHD Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. ADHD Companies and Universities
6.1 Leading ADHD companies researching in drug development
6.2 Leading ADHD Universities/Institutes investing in drug development
7. ADHD News and Deals
7.1 Recent ADHD Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact